The government has exempted drugs and pharmaceuticals from the the levy of Education Cess and Secondary and Higher Education Cess, resulting into reduction of excise duty from 6.18% to 6%, National Pharmaceutical Pricing Authority (NPPA) said in notification.
In exercise of the powers conferred on it by Drugs (Prices Control) Order, 2013, the NPPA "directs all the manufacturers to ensure to revise their Maximum Retail price (MRP), inclusive of excise duty and all taxes, of all formulation packs downward, pursuant to aforesaid notifications dated March 1, 2015," it added.
The above reduction in the MRP shall take effect immediately, NPPA said.
"However, where no excise duty has been actually paid/ payable to the government and no excise duty is chargeable in the MRP of such formulation packs, the reduction in prices of those formulation packs may not apply to the categories of concerned formulation packs," it added.
Established in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharmaceutical products (bulk drugs and formulations), enforcement of provisions of the Drugs (Prices Control) Order and monitoring of the prices of controlled and decontrolled drugs in the country.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)